Host: Rabbit
Target Protein: DEPDC1B/BRCC3
Immunogen Range: 451-529/529
Clonality: Polyclonal
Isotype: IgG
Entrez Gene: 55789
Swiss Prot: Q8WUY9
Source: KLH conjugated synthetic peptide derived from human DEPDC1B
Purification: Purified by Protein A.
Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage: Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
Background:
Size: 100ul
Concentration: 1ug/ul
Applications:
WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
Predicted Molecular Weight: 62
Cross Reactive Species: Human
Predicted Cross Reactive Species:
Mouse
Rat
Cow
Rabbit
For research use only. Not intended for diagnostic or therapeutic use.
- Bai, Shoumin, et al. "High levels of DEPDC1B predict shorter biochemical recurrence‑free survival of patients with prostate cancer." Oncology Letters.Read more>>
- Bai et al. High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer. (2017) Oncol.Let. 14:6801-6808Read more>>
- Ma X et al. High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer. (2018) Oncology Letters. 16: 6749-6755Read more>>
- Ma et al. High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer. (2018) Oncol.Lett. 16:6749-6755Read more>>
- Z-D Liu. et al. Aberrantly high DEPDC1B expression leads to poor prognosis in patients with lower-grade gliomas. EUR REV MED PHARMACO. 2022 Nov;26(21):7813-7826Read more>>
- Hairong Fei. et al. DEPDC1B enhances malignant phenotypes of multiple myeloma through upregulating CCNB1 and inhibiting p53 signaling pathway. TISSUE CELL. 2024 Feb;86:102263Read more>>
Formalin-fixed and paraffin embedded human brain glioma labeled with Anti-DEPDC1B Polyclonal Antibody, Unconjugated (bs-14278R) at 1:500 followed by conjugation to the secondary antibody and DAB staining.
Lane 1: HepG2 cell lysates; Lane 2: A549 cell lysates probed with DEPDC1B/BRCC3 Polyclonal Antibody, Unconjugated (bs-14278R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.
Lane 1: Human HepG2 cell lysates; Lane 2: Human MCF-7 cell lysates probed with DEPDC1B/BRCC3 Polyclonal Antibody, Unconjugated (bs-14278R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.